These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Tobramycin in patients with cystic fibrosis. Adjustment in dosing interval for effective treatment. Horrevorts AM; de Witte J; Degener JE; Dzoljic-Danilovic G; Hop WC; Driessen O; Michel MF; Kerrebijn KF Chest; 1987 Nov; 92(5):844-8. PubMed ID: 3665599 [TBL] [Abstract][Full Text] [Related]
13. Monitoring of tobramycin levels in patients with cystic fibrosis by finger-prick sampling. Jones A; Beisty J; McKenna D; Clough D; Webb K; Morris J; Keevil B Eur Respir J; 2012 Jun; 39(6):1537-8. PubMed ID: 22654009 [No Abstract] [Full Text] [Related]
14. Parenteral administration of tobramycin for pulmonary exacerbations in cystic fibrosis patients: toxicity, serum levels and efficacy. Braccini G; Lori I; Neri AS; Festini F; Pela I; Ciuti R; Boni V; Zavataro L; Braggion C; De Martino M; Taccetti G J Chemother; 2009 Feb; 21(1):101-4. PubMed ID: 19297282 [No Abstract] [Full Text] [Related]
15. Assessment of potential ototoxicity following high-dose nebulized tobramycin in patients with cystic fibrosis. Mukhopadhyay S; Baer S; Blanshard J; Coleman M; Carswell F J Antimicrob Chemother; 1993 Mar; 31(3):429-36. PubMed ID: 8486576 [TBL] [Abstract][Full Text] [Related]
16. Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis. Hennig S; Holthouse F; Staatz CE Clin Pharmacokinet; 2015 Apr; 54(4):409-21. PubMed ID: 25403847 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and Tolerability of Once Daily Double Dose Tobramycin Inhalation in Cystic Fibrosis Using Controlled and Conventional Nebulization. van Velzen AJ; Bos AC; Touw DJ; Tiddens HA; Heijerman HG; Janssens HM J Aerosol Med Pulm Drug Deliv; 2016 Jun; 29(3):273-80. PubMed ID: 26716357 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of once-daily versus thrice daily tobramycin in cystic fibrosis patients. Guglielmo BJ; Quan LA; Stulbarg MS J Antimicrob Chemother; 1996 May; 37(5):1040-2. PubMed ID: 8737161 [No Abstract] [Full Text] [Related]
19. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Gibson RL; Emerson J; McNamara S; Burns JL; Rosenfeld M; Yunker A; Hamblett N; Accurso F; Dovey M; Hiatt P; Konstan MW; Moss R; Retsch-Bogart G; Wagener J; Waltz D; Wilmott R; Zeitlin PL; Ramsey B; Am J Respir Crit Care Med; 2003 Mar; 167(6):841-9. PubMed ID: 12480612 [TBL] [Abstract][Full Text] [Related]
20. Tobramycin therapy of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis: effect of dosage and concentration of antibiotic in sputum. McCrae WM; Raeburn JA; Hanson EJ J Infect Dis; 1976 Aug; 134 Suppl():S191-3. PubMed ID: 972281 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]